from here: https://www.ncbi.nlm.nih.gov/pmc/arti
Post# of 153834
(Total Views: 553)
Posted On: 06/17/2022 7:56:48 AM
from here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819204/#SD1
There are 4 ligands of the CCR5 receptor.
I would say the polar opposite is true of Leronlimab. Leronlimab may be characterized as an agonist of CCR5 which serves to stabilize CCR5 in an active conformation thereby permitting communication to continue.
Using same statement on RANTES, I would say, RANTES may be characterized as an antagonist of CCR5 rendering CCR5 destabilized and in an inactive conformation thereby non conducive to intracellular communication.
Yeah, Leronlimab does the opposite. It stabilizes but permits chemokine communication.
CCR5 has 3 N-terminus. I would say LL binds to all 3. That is to say, I would not be surprised that for each CCR5 receptor, 3 LL may be bound to it.
CCR5 also has ECL1 and ECL2 as binding sites for the other ligands MIP-1α, MIP-1β, and MCP-2; RANTES uses the N-terminus as does HIV.
LL does not bind to ECL1 or ECL2. Those sites remain available for communication and are not hindered when LL binds to CCR5. RANTES is left in the cold.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3819204/#SD1
Quote:
The chemokine receptor CCR5 binds and responds to four endogenous chemokine agonists, RANTES, MIP-1α, MIP-1β, and MCP-2 (3).
There are 4 ligands of the CCR5 receptor.
Quote:
Maraviroc has been characterized as an inverse agonist of CCR5 (17), suggesting that Maraviroc stabilizes CCR5 in an inactive conformation.
I would say the polar opposite is true of Leronlimab. Leronlimab may be characterized as an agonist of CCR5 which serves to stabilize CCR5 in an active conformation thereby permitting communication to continue.
Using same statement on RANTES, I would say, RANTES may be characterized as an antagonist of CCR5 rendering CCR5 destabilized and in an inactive conformation thereby non conducive to intracellular communication.
Quote:
Thus, the CCR5/Maraviroc structure indicates that Maraviroc most likely inhibits chemokine function by blocking receptor activation through interactions with Site 2, which explains the allosteric inhibition of chemokine signaling by Maraviroc. ... Maraviroc may reduce chemokine and gp120 binding in an allosteric inverse agonism manner by stabilizing CCR5 in an inactive conformation . Thus, Maraviroc may alter chemokine signaling and gp120 binding by allosterically blocking agonist recognition and/or inhibiting receptor activation .
Yeah, Leronlimab does the opposite. It stabilizes but permits chemokine communication.
Quote:
Additionally, the N-terminus of CXCR4 contains nine acidic residues, while CCR5 only has three (Fig. 3, C, F and figure S6A).
CCR5 has 3 N-terminus. I would say LL binds to all 3. That is to say, I would not be surprised that for each CCR5 receptor, 3 LL may be bound to it.
CCR5 also has ECL1 and ECL2 as binding sites for the other ligands MIP-1α, MIP-1β, and MCP-2; RANTES uses the N-terminus as does HIV.
LL does not bind to ECL1 or ECL2. Those sites remain available for communication and are not hindered when LL binds to CCR5. RANTES is left in the cold.
(2)
(0)